Beneficial effect of long-chain n-3 polyunsaturated fatty acid supplementation on tuberculosis in mice.
Arista Nienaber, Mumin Ozturk, Robin C Dolman...
https://pubmed.ncbi.nlm.nih.gov/34082319/Actively Recruiting
Led by North-West University, South Africa · Updated on 2026-09-09
40
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are studying adults aged 18 to 45 years with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis. This trial evaluates whether adding omega-3 long-chain polyunsaturated fatty acids n-3 LCPUFA to standard tuberculosis treatment can shorten the time it takes for sputum cultures to become positive, reduce inflammation, and improve treatment outcomes compared to a placebo. The study is a randomized controlled trial designed to assess early bactericidal activity, early inflammatory response, and safety of the supplementation. Participants are randomly assigned to receive either approximately 2 grams of omega-3 fatty acids EPA and DHA daily through three 1-gram fish oil capsules or a matching placebo of high linoleic sunflower oil capsules. This supplementation is given alongside the intensive phase of tuberculosis treatment for eight weeks. The study includes a parallel comparison between the omega-3 group and the placebo group. During the study, participants attend a baseline clinical visit followed by mostly weekly follow-up visits for two months, then monthly visits for four months during the continuous phase of tuberculosis treatment. They provide blood, sputum, and urine samples for biomarker and metabolomic analyses and undergo assessments of iron status, body composition, and muscle strength. Researchers measure sputum culture time to positivity at multiple points and monitor inflammatory markers, safety, and clinical outcomes throughout the trial.
CONDITIONS
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
T
Tumelo Dr
Z
Ziska Pretorius, B. Cur
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
North-West University, South Africa
Lead Sponsor
Perinatal HIV Research Unit of the University of the Witswatersrand
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 weeks
Participants receive either omega-3 fatty acid supplements or placebo capsules daily for eight weeks alongside intensive tuberculosis treatment.
Weekly visits for 2 months, then monthly visits for 4 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Arista Nienaber, Mumin Ozturk, Robin C Dolman...
https://pubmed.ncbi.nlm.nih.gov/34082319/Vollico Nenni, Heda Melinda Nataprawira, Tetty Yuniati
https://pubmed.ncbi.nlm.nih.gov/24437320/Frank Ekow Atta Hayford, Robin Claire Dolman, Renee Blaauw...
https://pubmed.ncbi.nlm.nih.gov/32847532/Frank E A Hayford, Robin C Dolman, Mumin Ozturk...
https://pubmed.ncbi.nlm.nih.gov/34504860/North-West University, South Africa
Lead Sponsor
Perinatal HIV Research Unit of the University of the Witswatersrand
Collaborating Sponsor